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INTRODUCTION 
Although the importance of HLA in kidney and probably 
in heart transplantation (1-5) is recognized, the role of 
HLA in liver transplantation remains uncertain. Earlier 
studies at our institution could not show a beneficial 
effect of HLA compatibility on liver transplant survival 
(6,7). Also, the degree of pretransplant sensitization 
measured by panel-reactive antibody nor a positive 
crossmatch for donor-specific preformed antibody was 
associated with diminished liver transplant survival (8-10). 
In fact, our experience with combined liver-kidney 
transplants suggests that preformed donor-specific 
antibodies can be removed from the circulation by the liver 
allograft without apparent adverse effects and that the 
subsequent kidney transplant functions well without any 
evidence of hyperacute rejection (11). Studies by others 
have suggested that in ce rta in instances, the 1 i ve r 
allograft may undergo hyperacute rejection (12). 
Presensitization and donor-specific positive crossmatches 
have also been shown to be associated with increased 
incidence of "vanishing bi le duct" syndrome in 1 iver 
transplant recipients (13). Studies in our laboratory on 
liver transplant biopsy grown lymphocytes have shown the 
presence of alloreactive T cells specific for donor HLA 
antigens (14,15). 
We have recent 1 y reexami ned the quest i on of donor HLA 
compatibility and liver transplant survival. Our results 
have confirmed our previous findings that serologically 
defined HLA compatibility is not associated with improved 
liver transplant outcome. In fact, our data seem to suggest 
an opposite effect. 
MATERIALS AND METHODS 
Between March 1980 and Decembe r 1985, 667 orthotop i c 
liver transplants were performed. 517 patients received 
first allografts, while second and third transplants were 
done in 150 patients. All patients have been followed 
through August 15, 1986 and received cyclosporine and 
ste ro ids as i mmunosupp ress i ve drugs. As of Decembe r 1984 
OKT3 monoclonal antibody therapy has been added to treat 
acute rejection episodes. Tissue typing was done 
retrospectively and played no role in recipient selection. 
The age range of pat i ents was 4 months to 67 year s 
(mean 25.3 + 18.1 SO years) including 310 adults given 385 
g rafts and 210 ch i 1 d ren given 282 grafts. The most common 
primary indications for liver replacement were cirrhosis 
(25.0%), biliary atresia (20.3%), primary biliary cirrhosis 
(17.2%), inborn errors of metabolism (13.0%), sclerosing 
cholangitis (8.1%) and primary liver tumors (3.9%). 
Actuarial graft survival for different patient groups, 
who received liver transplants with various degrees of HLA 
compatibility, was calculated by the life table method. 
Criteria for transplant failures included patient death and 
allograft removal regardless of graft function. Statistical 
analysis of survival rates was done by the Breslow 
(generalized Wilcoxon) and Mantel-Cox (generalized Savage) 
tests us i ng the BMDPC software package (11). The Bres 1 ow 
test is we i ghted toward ear 1 i e r events and the Mante l-Cox 
test is weighted toward later events. 
RESULTS 
Complete typing data for HLA-A and HLA-B antigens was 
available for 332 donor-recipient pairs, 258 of which had 
primary transplants. Actuarial one year survival of primary 
grafts with no mismatch at the HLA-A locus (n=21) was 33.0%, 
with one mismatch (n=101) 60.8%, and with a complete 
mismatch (n=136) 58.7% (Figure 1).' The survival of liver 
allografts with zero HLA-A antigen mismatches was less than 
those wi th one or two HLA-A ant i gen mi smatches (Bres 1 ow 
p=0.125, Mantel-Cox p=0.054). HLA-B typing data showed 
57.8% survival of allografts with one mismatch (n=50) and 
57.4% survival for allografts with two mismatches (n=204). 
Only 4 patients received a liver with zero HLA-8 mismatches 
and the one year graft surv i va 1 was 50%. The numbers of 
transplants was too small for statistical analysis of HLA-B 
compatibility differences in these groups. 
For 292 donor-recipient combinations, we had complete 
typing data for HLA-DR antigens, 224 of which were primary 
transplants. Actuarial one year graft survival with zero DR 
mismatch (n=17) was 41.2%, whereas one DR mismatched (n=62) 
and two DR mismatched (n=145) liver allografts had one year 
survivals of 56.0% and 59.7%, respectively (Figure 2). 
Statistical analysis showed that zero DR mismatched 1 iver 
transplant had borderline significantly lower survival rates 
than one and two DR mi smatched 1 i ve r transp 1 ants (Bres 1 ow 
p=0.053; Mandel-Cox p=0.066). 
DISCUSSION 
This study confirms a previous report that HLA 
compatibility has no beneficial effect on liver transplant 
surv i va 1 . In fact we observed a trend that at 1 east for 
HLA-A and HLA-DR, compatibility might be associated with a 
decreased survival of liver allografts. The statistical 
analysis of differences reached borderline levels of 
significance, but a larger group of patients is needed 
before definite conclusions can be made about possible 
adverse effects of HLA compatibility on liver transplant 
outcome. Nevertheless, our findings are compatible with 
recent observations by others of an association between HLA 
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incompatibility and liver transplant dysfunction due to 
"vanishing bile duct" syndrome (13). 
Although the findings reported here, must be considered 
preliminary, we have considered various explanations why HLA 
compatibility might adversely affect liver transplants. A 
consideration is that liver transplants may be 
physiologically and anatomically different from other solid 
organ transplants. This is apparent from the high success 
rate of liver transplants from crossmatch positive donors 
suggesting perhaps the relative resistance of the liver 
allograft to the deleterious effects of donor-specific 
antibody. Liver transplant recipients experience acute 
rejection episodes and functional studies on biopsy grown 
1 ymphocytes have shown that 1 ymphocytes i nf i 1 trat i ng 1 i ver 
transplants recognize donor HLA antigens (14,15). In 
analogy to other organ transplants, it is reasonable to 
postulate that HLA antigens are involved in liver transplant 
rejection. 
On the other hand, additional immunological effector 
mechanisms unrelated to rejection, may contribute to 
irreversible liver dysfunction. These cellular immune 
react ions may have vi ra 1 and autoi mmune et i 01 og i es. An 
important consideration is the nature of the primary disease 
of many liver transplant recipients. In this regard HLA, 
may-through its ability to function as a _restriction element 
( 16) promote the rec i pi ent' s immune response to vi ra 1 or 
autoant i gens, thereby caus i ng increased dysfunct i on of an 
HLA compatible liver allograft. This would explain why HLA 
compatible liver transplants may show under certain 
circumstances inferior survival. Thus, HLA compatibility 
may have a dualistic effect on liver transplant outcome, on 
one hand it may reduce rejection whereas on the other hand, 
it may enhance other cellular immune mechanisms leading to 
graft dysfunction. 
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FIGURE LEGENDS 
Figure 1: Actuarial survival for 258 primary liver 
transplants for which tissue typing data of the HLA-A locus 
was available. 
Figure 2: Actuarial survival for 224 primary liver 
transplants for which tissue typing data of the HLA-DR locus 
was available. 
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